[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX337060B - Proceso para preparar una composicion de inmunoglobulina. - Google Patents

Proceso para preparar una composicion de inmunoglobulina.

Info

Publication number
MX337060B
MX337060B MX2012012262A MX2012012262A MX337060B MX 337060 B MX337060 B MX 337060B MX 2012012262 A MX2012012262 A MX 2012012262A MX 2012012262 A MX2012012262 A MX 2012012262A MX 337060 B MX337060 B MX 337060B
Authority
MX
Mexico
Prior art keywords
preparing
immunoglobulin composition
immunoglobulin
composition
immunoglobulins
Prior art date
Application number
MX2012012262A
Other languages
English (en)
Other versions
MX2012012262A (es
Inventor
Wolfgang Möller
Dieter Rudnick
Oliver Maneg
Michael Rodemer
Herbert Dichtelmueller
Eckhard Flechsig
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42270688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337060(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of MX2012012262A publication Critical patent/MX2012012262A/es
Publication of MX337060B publication Critical patent/MX337060B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de una composición de inmunoglobulina a partir de una fracción de plasma que comprende inmunoglobulinas, y preparaciones de anticuerpo preparados utilizando el proceso.
MX2012012262A 2010-04-22 2011-04-21 Proceso para preparar una composicion de inmunoglobulina. MX337060B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1006753.6A GB201006753D0 (en) 2010-04-22 2010-04-22 Process for preparing an immunolobulin composition
PCT/EP2011/056486 WO2011131786A2 (en) 2010-04-22 2011-04-21 Process for preparing an immunoglobulin composition

Publications (2)

Publication Number Publication Date
MX2012012262A MX2012012262A (es) 2012-11-23
MX337060B true MX337060B (es) 2016-02-09

Family

ID=42270688

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012263A MX338195B (es) 2010-04-22 2011-04-21 Preparaciones de anticuerpos.
MX2012012262A MX337060B (es) 2010-04-22 2011-04-21 Proceso para preparar una composicion de inmunoglobulina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012012263A MX338195B (es) 2010-04-22 2011-04-21 Preparaciones de anticuerpos.

Country Status (20)

Country Link
US (6) US9243056B2 (es)
EP (2) EP2560682B2 (es)
JP (4) JP6118248B2 (es)
KR (2) KR101872747B1 (es)
CN (3) CN102939107B (es)
AU (2) AU2011244241B2 (es)
BR (2) BR112012026937A2 (es)
CA (2) CA2796263C (es)
CO (2) CO6640238A2 (es)
ES (2) ES2553385T3 (es)
GB (1) GB201006753D0 (es)
HK (2) HK1177600A1 (es)
HU (2) HUE025853T2 (es)
IL (2) IL222374A (es)
MX (2) MX338195B (es)
PL (2) PL2560682T5 (es)
RU (4) RU2749732C2 (es)
SG (2) SG184844A1 (es)
WO (2) WO2011131787A2 (es)
ZA (2) ZA201208541B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2959821B1 (fr) * 2010-05-05 2012-07-06 Lab Francais Du Fractionnement Procede de mesure de l'activation du complement par des igg
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
RU2644240C2 (ru) 2012-03-09 2018-02-08 Цсл Беринг Аг Композиции, содержащие секреторноподобные иммуноглобулины
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
KR20150115639A (ko) * 2014-04-04 2015-10-14 전숙영 치료용 면역글로불린 제제 제조에 사용되는 산성 완충액, 이를 이용한 치료용 면역글로불린 제제 제조방법 및 이 제조방법으로 제조된 치료용 면역글로불린 제제
WO2016011054A2 (en) * 2014-07-15 2016-01-21 The Regents Of The University Of California Novel treatment for polycystic kidney disease
SI3334747T1 (sl) 2015-08-13 2024-02-29 Amgen Inc. Globinsko nabito filtriranje proteinov, ki vežejo antigen
ES2881201T3 (es) 2016-03-14 2021-11-29 Biotest Ag Tratamiento de la neumonía grave adquirida en la comunidad
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
RU2660584C1 (ru) * 2017-06-06 2018-07-06 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ определения FC-функции препаратов иммуноглобулина человека
KR102551444B1 (ko) * 2017-11-29 2023-07-06 에프. 호프만-라 로슈 아게 표적 간섭이 억제된 항-약물 항체 분석
EP3747903A1 (en) 2019-06-07 2020-12-09 Biotest AG Method and kit for testing potency of immunoglobulin compositions
EP4132573A1 (en) * 2020-04-10 2023-02-15 Vanudis GmbH Natural antibodies in prophylaxis and therapy
WO2021244910A1 (en) * 2020-06-03 2021-12-09 Grifols Worldwide Operations Limited Hyperimmune igg and/or igm compositions and method for preparing thereof and method for obtaining hyperimmune human plasma from a donor
JP2023532473A (ja) * 2020-07-10 2023-07-28 グリフォルス・ワールドワイド・オペレーションズ・リミテッド ヒト血漿由来免疫グロブリンｍを含む組成物を得るための方法
CN111944043B (zh) * 2020-09-01 2023-05-09 华兰生物工程重庆有限公司 一种从血浆废弃物中提取IgM的方法
US20230400453A1 (en) 2020-11-19 2023-12-14 Biotest Ag Method and Kit for Testing Immunomodulatory Potency of Immunoglobulin Compositions for Treatment of COVID-19
MX2024001187A (es) 2021-07-29 2024-02-27 Csl Behring Ag Metodo para purificar inmunoglobulina g y usos de la misma.
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US136556A (en) 1873-03-04 Improvements in button-fastenings
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
US4371520A (en) * 1981-10-28 1983-02-01 The Green Cross Corporation Process for preparing immunoglobulin suitable for intravenous injection
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
IL90281A (en) † 1988-06-06 1994-10-07 Miles Inc Preparations containing MGI antibodies
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US4939176A (en) 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
DE3927111C3 (de) 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
DE3927112C1 (es) * 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
ES2290957T3 (es) 1995-07-14 2008-02-16 Caf - Dcf Cvba - Scrl Instalacion de desactivacion de contaminantes virales presentes en productos sanguineos.
DK0764658T3 (da) 1995-09-22 2002-04-22 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af immunoglobuliner ud fra fraktioner, som opstår ved fraktionering af blodplasma fra mennesker
EP0835880A1 (de) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
JP3987599B2 (ja) * 1996-12-05 2007-10-10 日本製薬株式会社 筋ジストロフィー治療剤
JPH10167894A (ja) * 1996-12-11 1998-06-23 Mitsubishi Gas Chem Co Inc ビスマス置換希土類鉄ガーネット単結晶膜の製造法
US5886154A (en) † 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
EP1493751A1 (en) 1998-06-09 2005-01-05 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
RU2178309C2 (ru) * 2000-01-12 2002-01-20 Российский научно-исследовательский институт геронтологии Антитимоцитарный глобулин для внутривенного введения и способ его получения
RU2192279C2 (ru) * 2000-09-07 2002-11-10 Нижегородское государственное предприятие по производству бактерийных препаратов Способ получения иммуноглобулинового препарата
WO2002038191A2 (en) † 2000-11-13 2002-05-16 Bayer Aktiengesellschaft Method of inactivating microorganisms in a fluid using ultraviolet radiation
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003037504A1 (fr) † 2001-11-02 2003-05-08 Japan Techno Co., Ltd. Agitateur vibratoire pour sterilisation et sterilisateur ainsi que procede de sterilisation faisant appel a cet agitateur vibratoire
RU2255766C2 (ru) * 2003-03-05 2005-07-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габрического Министерства здравоохранения Российской Федерации" Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата
CA2520381A1 (en) 2003-03-26 2004-10-14 Sudhir Paul Proteolytic and covalent antibodies
BRPI0415887B1 (pt) † 2003-10-27 2021-01-26 Wyeth métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
EP1718675B2 (en) † 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
ATE469658T1 (de) 2004-12-10 2010-06-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
KR101157174B1 (ko) † 2005-11-24 2012-06-20 삼성전자주식회사 세포 또는 바이러스의 신속한 파괴 방법 및 장치
DE102005062634A1 (de) 2005-12-23 2007-06-28 Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung
FR2899112B1 (fr) * 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines et de fragments f (ab)'2 et/ou fab specifiques d'un arbovirus en tant que medicament.
FR2899111B1 (fr) 2006-03-31 2010-09-03 Lab Francais Du Fractionnement Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament.
US8354076B2 (en) † 2006-10-02 2013-01-15 Palo Alto Research Center Incorporated Fluid stirring mechanism
EP1950225A1 (de) 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
CN102089005A (zh) 2008-05-12 2011-06-08 斯特罗克斯生物制药有限责任公司 金黄色葡萄球菌特异性抗体制剂
RU2457863C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
RU2457861C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Композиция, обладающая противовирусным и антимикробным действием, содержащая консорциум иммуноглобулинов
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
NZ591514A (en) 2011-03-03 2013-11-29 Kode Biotech Ltd Assay method

Also Published As

Publication number Publication date
US20130045199A1 (en) 2013-02-21
CN102939107B (zh) 2016-12-21
JP2016196477A (ja) 2016-11-24
US20130052208A1 (en) 2013-02-28
EP2560682B2 (en) 2024-01-17
IL222374A (en) 2017-04-30
BR112012026937A2 (pt) 2016-07-12
RU2016140455A3 (es) 2020-04-02
MX2012012263A (es) 2012-11-23
EP2560691A2 (en) 2013-02-27
EP2560691B1 (en) 2015-11-04
CN102939111B (zh) 2014-10-29
JP6283517B2 (ja) 2018-02-21
US11780909B2 (en) 2023-10-10
AU2011244240A1 (en) 2012-12-06
HK1180601A1 (zh) 2013-10-25
KR101860459B1 (ko) 2018-05-23
WO2011131787A2 (en) 2011-10-27
RU2765738C2 (ru) 2022-02-02
US10059759B2 (en) 2018-08-28
HUE025853T2 (en) 2016-05-30
RU2012149743A (ru) 2014-05-27
JP2016222674A (ja) 2016-12-28
RU2017111820A (ru) 2019-01-24
CN102939111A (zh) 2013-02-20
KR20130094718A (ko) 2013-08-26
AU2011244241A1 (en) 2012-12-06
AU2011244241B2 (en) 2014-12-04
IL222374A0 (en) 2012-12-31
WO2011131786A3 (en) 2011-12-22
CO6640238A2 (es) 2013-03-22
CA2796263A1 (en) 2011-10-27
HK1177600A1 (zh) 2013-08-23
SG184844A1 (en) 2012-11-29
US20150064170A1 (en) 2015-03-05
CA2796409A1 (en) 2011-10-27
RU2749732C2 (ru) 2021-06-16
PL2560682T5 (pl) 2024-04-29
ES2551605T5 (es) 2024-06-27
JP6118248B2 (ja) 2017-04-19
JP2013530950A (ja) 2013-08-01
CN102939107A (zh) 2013-02-20
SG184843A1 (en) 2012-11-29
PL2560691T3 (pl) 2016-04-29
CN107080842A (zh) 2017-08-22
WO2011131787A3 (en) 2011-12-22
JP2013531630A (ja) 2013-08-08
EP2560682A2 (en) 2013-02-27
ES2553385T3 (es) 2015-12-09
IL222373A (en) 2016-02-29
EP2560682B1 (en) 2015-10-21
BR112012026934A2 (pt) 2015-09-22
KR101872747B1 (ko) 2018-06-29
RU2617532C2 (ru) 2017-04-25
MX338195B (es) 2016-04-06
AU2011244240B2 (en) 2014-12-04
CA2796263C (en) 2019-05-14
MX2012012262A (es) 2012-11-23
US20180319871A1 (en) 2018-11-08
PL2560682T3 (pl) 2016-04-29
KR20130060199A (ko) 2013-06-07
ES2551605T3 (es) 2015-11-20
HUE028581T2 (en) 2016-12-28
US9243056B2 (en) 2016-01-26
US20170058020A1 (en) 2017-03-02
US8900806B2 (en) 2014-12-02
IL222373A0 (en) 2012-12-31
RU2017111820A3 (es) 2020-07-20
WO2011131786A2 (en) 2011-10-27
US20210179694A1 (en) 2021-06-17
RU2016140455A (ru) 2018-12-17
JP6612186B2 (ja) 2019-11-27
CO6640239A2 (es) 2013-03-22
RU2612899C2 (ru) 2017-03-13
ZA201208540B (en) 2015-06-24
GB201006753D0 (en) 2010-06-09
ZA201208541B (en) 2015-06-24
US10954290B2 (en) 2021-03-23
RU2012149741A (ru) 2014-05-27
JP6612182B2 (ja) 2019-11-27
US9518110B2 (en) 2016-12-13

Similar Documents

Publication Publication Date Title
MX337060B (es) Proceso para preparar una composicion de inmunoglobulina.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX347020B (es) Anticuerpo contra el csf-1r.
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
MY187990A (en) Anti-cd40 antibodies
UA101487C2 (en) Humanized b-ly1 antibody formulation
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EP3786183A3 (en) Antigen binding constructs to cd3
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
IL222359A0 (en) Monoclonal antibodies against her2 antigens, and uses therefor
HUE062385T2 (hu) Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MY170720A (en) Antibody formulations
AU2012208283A8 (en) Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
NZ604464A (en) Anti-vegf antibodies and uses thereof
AU2012278751A8 (en) AGR2 blocking antibody and use thereof
IL232976A0 (en) Antibodies that bind to epitopes of the influenza A virus, preparations containing them and methods for their preparation
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
WO2014064712A3 (en) An improved process for the preparation of fulvestrant

Legal Events

Date Code Title Description
FG Grant or registration